About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  Press Releases
  Media Stories
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts

Press Releases

2020 2019 2018 2017
2016 2015 2014 2013 2012 2011
2010 2009 2008 2007 2006 2005

  December 2018
19 Dec Company Statement : Biosimilar Trastuzumab Co-Developed by Biocon Receives Approval in the EU Download Pdf
17 Dec Company Statement : Biocon's APIs Manufacturing Facility in Telangana Completes U.S. FDA Inspection with No 483 Observations Download Pdf
02 Dec Biocon Foundation Dedicates Rejuvenated Hebbagodi Lake and Children's Park to the Community Download Pdf
  November 2018
30 Nov Company Statement : Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU Download Pdf
12 Nov Company Statement : Biocon's Generic Formulations Facility in Bengaluru completes U.S. FDA Inspection with No 483 observations Download Pdf
  October 2018
30 Oct Biocon Ranked 7th on Top Global Pharma & Biotech Employers List 2018 Download Pdf
25 Oct Biocon Q2FY19 Revenue at Rs 1,375 Cr, Up 35%; EBITDA at Rs 394 Cr, Up 69%; Net Profit at Rs 355 Cr; Net Profit (excluding exceptional income) at Rs 184 Cr; Up 167% Download Pdf
19 Oct Biocon and Mylan Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab Download Pdf
  September 2018
22 Sept Company Statement : Biocon’s Drug Substance Facility in Bangalore completes US FDA Inspection with No observations Download Pdf
21 Sept Biocon and Mylan Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim Download Pdf
  July 2018
26 July Biocon Q1FY19 Revenue Rs 1,193 Cr, Up 21%; EBITDA Up 25% at Rs 307 Cr; Net Profit Up 47% at Rs 120 Cr Download Pdf
04 July Company Statement: Biocon's Sterile Drug Product facility receives EU GMP Certification Download Pdf
  June 2018
28 June Kiran Mazumdar-Shaw Elected Full-Term Member of the Board of Trustees of MIT, USA Download Pdf
28 June Company Statement: Biocon retains economic interest in Etanercept collaboration with Mylan Download Pdf
23 June Company Statement: Biocon’s Sterile Drug Product facility Receives EIR from U.S. FDA Download Pdf
04-05 June U.S. FDA Approves Mylan and Biocon’s Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta® Download Pdf
04 June Tata Memorial Hospital Team Presents Biocon’s Nimotuzumab Study Results at ASCO Annual Meeting 2018 Download Pdf
02 June Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin®, approved by US FDA Download Pdf
02 June Company Statement : Biocon Update on Insulin Glargine Download Pdf
  May 2018
02 May Company Statement: Biocon Regulatory Audit Update Download Pdf
  April 2018
26 Apr Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr Download Pdf
18 Apr Kiran Mazumdar-Shaw #1 Business Captain in 'The Medicine Maker 2018 Power List' Download Pdf
11 Apr Company Statement: Mylan and Biocon seek to accelerate introduction of Adalimumab biosimilar in EU Download Pdf
  March 2018
28 Mar Mylan and Biocon Receive Approvals from the European Commission and TGA, Australia for SemgleeTM Biosimilar Insulin Glargine Download Pdf
13 Mar Update on Company Statement on US-FDA Inspection at Biocon Malaysia Download Pdf
  February 2018
21 Feb Company Statement on US-FDA Inspection at Biocon Malaysia Download Pdf
  January 2018
29 Jan Mylan and Biocon Receive Positive CHMP Opinion for SemgleeTM, Biosimilar Insulin Glargine Download Pdf
24 Jan Biocon Q3FY18 Revenue at Rs 1092 Crore; EBITDA at Rs 256 Crore; Net Profit at Rs 92 Crore Download Pdf
18 Jan Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars Download Pdf
Enduring Edge: The Narrative from Annual Report 2018: All About Biocon's Journey of Endurance  


Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved